Autolus Therapeutics
Autolus Therapeutics' revenue rose 644.9% to $75 million in fiscal 2025. Its operating margin was −358.9%, up from −2,385.6% a year earlier. Free cash flow was −$303 million. The diluted share count rose 4.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Autolus Therapeutics does
Autolus is an early commercial-stage biopharmaceutical company. It develops, makes and delivers T cell therapies, in which a patient's own immune cells are engineered to find and destroy cancer cells, and it is also testing them against autoimmune diseases.
Its first product, AUCATZYL (obe-cel), is a CAR T cell therapy for adults whose B-cell precursor acute lymphoblastic leukemia, a fast-growing blood cancer, has come back or not responded to treatment. The US Food and Drug Administration approved it in November 2024, and the first US sale came in January 2025. It has also been cleared in the United Kingdom and the European Union, and launched in the UK in January 2026. The company says its EU launch is on hold and it expects no EU sales of AUCATZYL in 2026.
Autolus makes AUCATZYL at its own site, the Nucleus, in Stevenage, UK. Cardinal Health is its commercial distribution partner in the US. It is also testing obe-cel in children with leukemia and lymphoma, and in people with severe lupus.
Its biggest risks, as it describes them
- Losses since it began, and the need for more funding to sell AUCATZYL and develop other candidates.
- AUCATZYL may not win enough acceptance from doctors, patients and insurers.
- Competition from CD19-targeted CAR T therapies from Novartis, Gilead and BMS.
- Obligations under license and collaboration deals, including with Blackstone, that limit its flexibility.
- Whether insurers will cover and reimburse its therapies at adequate rates.
Income statement
Autolus Therapeutics lost money in fiscal 2025: a net loss of $288 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 310 | 382 | 240 | 588 | 301 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −310 | −382 | −240 | −588 | −301 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −127.7x | −16.1x | −4.0x | −26.0x | −7.4x |
| Current ratio | 12.2x | 9.2x | 6.2x | 10.9x | 5.9x |
| Quick ratio | 12.2x | 9.2x | 6.2x | 10.8x | 5.5x |
Cash flow
Projections
Project Autolus Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Autolus Therapeutics shares on the open market, and 1 insider sold $15,708.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Cintia PiccinaU.S. CCO & Country Gen Manager | Sold | 6,713 | $2.34 | $15,708 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 3 of 9 | 3 of 9 |
| Rule of 40 | — | −1,760.4% | 243.5% |
| Altman Z'' | −6.37 | −0.36 | −6.27 |
| Accruals ratio | −14.5% | −2.5% | −0.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | Fail | Fail |
| Revenue rose relative to assets | — | Pass | Pass |
| F-score | — | 3 of 9 | 3 of 9 |
Compare
Put Autolus Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Autolus Therapeutics | FY25 | 644.9% | −358.9% | −401.4% | — | — | 3 | |
| AbCellera Biologics | FY25 | 160.6% | −289.0% | −231.7% | — | — | — | Compare |
| Recursion Pharmaceuticals | FY25 | 26.9% | −867.9% | −506.5% | −117.2% | — | 4 | Compare |
| CytomX Therapeutics | FY25 | −44.8% | −29.4% | −99.5% | — | — | — | Compare |
| Cellectis | FY25 | 75.8% | −45.3% | −57.2% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1 | 2 | 1 | 3 | — | — | — | 2 | 10 | 75 |
| Revenue growth | — | 39.7% | −16.9% | 106.7% | — | — | — | — | 496.0% | 644.9% |
| Gross profit | — | — | — | — | — | — | — | 2 | −1 | −21 |
| Research and development | 10 | 16 | 36 | 105 | 135 | 111 | 117 | 130 | 138 | 118 |
| Operating income | — | −23 | −58 | −146 | −168 | −141 | −143 | −180 | −241 | −270 |
| Net income | −12 | −20 | −45 | −124 | −142 | −142 | −149 | −208 | −221 | −288 |
| Diluted EPS (US$) | −1.26 | −1.43 | −1.42 | −2.88 | −2.76 | −1.97 | −1.57 | −1.20 | −0.86 | −1.08 |
| Diluted shares (millions) | 10 | 14 | 32 | 43 | 52 | 72 | 95 | 174 | 255 | 266 |
| Cash flow | ||||||||||
| Cash from operations | −10 | −16 | −32 | −102 | −118 | −118 | −112 | −146 | −206 | −284 |
| Capital expenditure | 2 | 3 | 9 | 18 | 15 | 9 | 11 | 11 | 22 | 19 |
| Free cash flow | −12 | −19 | −41 | −120 | −132 | −127 | −123 | −157 | −228 | −303 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 3 | 7 | 30 | 20 | 10 | 12 | 11 | 16 | 14 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 28 | 137 | 247 | 211 | 154 | 310 | 382 | 240 | 588 | 301 |
| Debt incl. finance leases | — | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | — | 149 | 273 | 304 | 294 | 406 | 490 | 375 | 783 | 589 |
| Total liabilities | — | 6 | 18 | 49 | 84 | 92 | 192 | 264 | 355 | 411 |
| Shareholders' equity | 31 | 143 | 256 | 255 | 210 | 313 | 299 | 112 | 427 | 178 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | 100.0% | −12.5% | −27.8% |
| Operating margin | — | −1,383.2% | −4,089.1% | −5,022.8% | — | — | — | −10,583.1% | −2,385.6% | −358.9% |
| Net margin | −1,035.5% | −1,165.2% | −3,180.6% | −4,258.9% | — | — | — | −12,272.3% | −2,180.4% | −381.4% |
| Free cash flow margin | −965.7% | −1,136.2% | −2,889.6% | −4,120.5% | — | — | — | −9,221.0% | −2,256.4% | −401.4% |
| Rule of 40 (growth + FCF margin) | — | −1,096.5% | −2,906.4% | −4,013.8% | — | — | — | — | −1,760.4% | 243.5% |
| Return on capital | — | — | — | — | −267.4% | — | — | — | — | — |
| Return on equity | — | — | −22.5% | −48.5% | −61.1% | −54.3% | −48.6% | −101.6% | −81.9% | −95.0% |
| Return on assets | — | — | −21.2% | −43.0% | −47.5% | −40.6% | −33.2% | −48.1% | −38.1% | −41.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |